NEWS |
ANti-AgEiNg tEchNiquES Not yEt AccEptEd
those who use milder techniques, such as sun avoidance and facial creams. furthermore, younger adults were found to be more negative about using anti-ageing methods than older adults. 'these results suggest that despite the rapid
S
growth of the anti-ageing cosmetic industry, age concealment has not yet become universally accepted,' said lead author of the study, alison chasteen. 'this is important because it shows that despite
the emphasis on looking younger in society, there are possible negative social consequences to fighting the signs of ageing by engaging in cosmetic age concealment.' the first study assessed the reactions of 122
younger (mean age 19 years) and 123 older adults (mean age 70 years) to middle aged (50-years-old) or older (60- to 70-years-old) people who used mild (facial creams) or major (botulinum toxin) anti- ageing methods. they also assessed the participants' perceptions of the middle aged or older adults' vanity and typicality to their age group. the study found that older adults had more
positive feelings towards those who used any type of anti-ageing techniques than the younger adults did. both groups viewed mild methods more favourably than major methods and both groups considered middle-aged people to be more 'typical' of those using anti-ageing techniques.
the second study broadened the age range
of the age concealment users, as well as the types of anti-ageing methods used. a total of 51 younger (mean age 19 years) and 49 older adults (mean age 70 years) were randomly assigned to read about either four middle-aged adults (aged in their 40s) or four older adults (60s) who used either natural (avoiding the sun), mild (facial creams), major (botulinum toxin), or extreme (brow lift) anti-ageing methods. Participants again indicated their overall reaction, how vain they thought the individuals were, and also how typical they felt the adults were of their age group. the study found similar results to the first, but
also that younger adults considered those using the natural and mild methods to be vainer than older adults did. older adult participants viewed older users of anti-ageing methods as more typical than middle-aged users, but young adult participants viewed the middle-aged and older users as equally typical.
tUdieS from tHe UniverSity of toronto's psychology department show that people who use more invasive anti-ageing methods such as botulinum toxin injections or surgery are viewed more negatively than
PETN in prevention of skin cancer
Scientists believe they have identified a role for PTEN, a known tumour suppressor, in removing DNA damage derived from UVB radiation, a known risk factor for non-melanoma skin cancer, according to a study published in Cancer Research. Yu-Ying He, Ph.D., an assistant
professor of medicine at the University of Chicago, found that laboratory mice with reduced levels of PTEN were more likely to have UVB-induced skin cancers. Non-melanoma skin cancer is the
most common cancer in the United States. The 1 million cases diagnosed last year accounted for 40& of all new diagnosed cancers. Scientists know that the major risk factor for this type of skin cancer is UVB radiation from sunlight, which leads to DNA damage. PTEN, which was first identified in
1997, promotes genomic stability and cellular repair and can lead to a reduction in the molecular misfiring that leads to cancer and tumour progression. In the current study, He and
colleagues exposed skin cells to UVB radiation and examined the rates of DNA repair. Those with lower PTEN levels had slower rates of DNA repair, because of loss of the key DNA repair protein xeroderma pigmentosum C (XPC). Importantly, if the scientists restored the levels of XPC, then the rates of DNA repair went up as well. He called the idea of a chemoprevention trial "promising," and said that her lab plans to assess the chemopreventive potential of restoring PTEN function.
Ipsen announce half-year 2011 results, showing a sustained growth
The Board of Directors of Ipsen (Euronext: IPN; ADR: IPSEY) met on 26 August 2011 to approve the financial statements for the first half 2011. The interim financial report, with regard to regulated information, is available on the Group's website,
www.ipsen.com, under the Regulated Information tab in the Investor Relations section. The 2011 half year financial
statements have been subject to a limited review by statutory auditors. Commenting on the first half
10 ❚
2011 performance, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen, said: 'With drug sales totalling
€567 million, up by 5.2% year-on- year excluding foreign exchange impacts, Ipsen has once again seen dynamic growth in its specialty care products. This sales performance has resulted in the Group increasing its financial objectives for the full year 2011. Taking into account the strategic review and the gradual re-focusing of the Group spending,
October 2011 |
prime-journal.com
particularly on the 10 phase III clinical trials currently underway, 2011 must be viewed as a transitional year in terms of profitability.' Marc de Garidel added: 'Since the announcement of the new strategy on 9 June, Ipsen has been gearing up to fulfilits 2020 ambition. To this end, all the positions in the Group's Executive Committee have now been filled and the administrative and employee-related procedures required for authorisation to close the Barcelona R&D site have been
completed. In Europe, we have just entered into an agreement in hemophilia with our partner Inspiration Biopharmaceuticals to build a strong commercial presence. 'Lastly, in North America, we began transferring our commercial activities to the East Coast. Now that we have laid down the foundations in our vision, we will introduce in the coming months the investments announced on 9 June.'
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84